Technical Analysis for INMB - INmune Bio Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| See historical INMB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Feb 14 | New 52 Week Closing Low | Bearish | 0.00% |
| Feb 14 | Hot IPO Pullback | Bullish Swing Setup | 0.00% |
| Feb 14 | New 52 Week Low | Weakness | 0.00% |
| Feb 13 | New 52 Week Closing Low | Bearish | -0.41% |
| Feb 13 | Hot IPO Pullback | Bullish Swing Setup | -0.41% |
| Feb 12 | Hot IPO Pullback | Bullish Swing Setup | -4.55% |
| Feb 11 | Hot IPO Pullback | Bullish Swing Setup | -4.42% |
| Feb 11 | Outside Day | Range Expansion | -4.42% |
| Feb 8 | Inside Day | Range Contraction | -4.67% |
| Feb 7 | New 52 Week Closing Low | Bearish | -2.78% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
INmune Bio (NASDAQ: INMB), Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.
Biotechnology Cancer Disease Solid Tumors Immunotherapy Immune System Cancer Treatments Hematologic Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Checkpoint Inhibitor
Biotechnology Cancer Disease Solid Tumors Immunotherapy Immune System Cancer Treatments Hematologic Malignancies Tumors Of The Hematopoietic And Lymphoid Tissues Checkpoint Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more INMB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 9.0 |
| 52 Week Low | 7.0 |
| Average Volume | 17,714 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 0.0 |
| 20-Day Moving Average | 0.0 |
| 10-Day Moving Average | 0.0 |
| Average True Range | 0.0 |
| ADX | 0.0 |
| +DI | 0.0 |
| -DI | 0.0 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.0 |
| Lower Bollinger Band | 0.0 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0 |
| MACD Line | 0.0 |
| MACD Signal Line | 0.0 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.03 | ||||
| Resistance 3 (R3) | 7.98 | 7.72 | 7.91 | ||
| Resistance 2 (R2) | 7.72 | 7.54 | 7.74 | 7.87 | |
| Resistance 1 (R1) | 7.53 | 7.44 | 7.63 | 7.58 | 7.84 |
| Pivot Point | 7.27 | 7.27 | 7.31 | 7.29 | 7.27 |
| Support 1 (S1) | 7.08 | 7.09 | 7.18 | 7.13 | 6.86 |
| Support 2 (S2) | 6.82 | 6.99 | 6.84 | 6.83 | |
| Support 3 (S3) | 6.63 | 6.82 | 6.79 | ||
| Support 4 (S4) | 6.68 |
